All stock lists
Alzamend Neuro, Inc. (NASDAQ:ALZN)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.11-0.02 (-1.77%)
Insider Score
––Not scored
ALZN Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ALZN Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 27.68 K | 27.68 K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.68 K | -27.68 K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 1.94 M | 2.44 M | 919.02 K | 821.83 K | 959.33 K | 688.78 K |
| R&D Expense | 1.09 M | 434.01 K | 1.28 M | 176.28 K | 1.74 M | 450.16 K |
| Operating Expenses | 3.00 M | 2.84 M | 2.20 M | 998.11 K | 2.70 M | 1.14 M |
| Operating Income | -3.03 M | -2.87 M | -2.20 M | -998.11 K | -2.70 M | -1.14 M |
| Pretax Income | -3.03 M | -2.87 M | -2.20 M | -1.00 M | -2.70 M | -1.14 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -3.03 M | -2.87 M | -2.20 M | -1.00 M | -2.70 M | -1.14 M |
| EPS (Basic) | -0.68 | -0.74 | -0.58 | -0.30 | -1.28 | -2.43 |
| EPS (Diluted) | -0.68 | -0.74 | -0.58 | -0.30 | -1.28 | -2.43 |
| Shares Outstanding | 4.48 M | 3.34 M | 3.80 M | 3.38 M | 2.11 M | 468.00 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.